menu
    • menu

    Company profile for Corxel Pharmaceuticals

    NEW Drugs in Dev: 7
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CORXEL, formerly Ji Xing Pharmaceuticals, is a leading biotech company focused on innovative cardiometabolic therapies. Backed by RTW Investments and founded in 2019, CORXEL combines cutting-edge science, a robust pipeline, and patient-centric values to make a global impact. With expertise in developing and delivering transformative medicines, CORXEL is committed to improving healthcare for underserved patients worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Corxel PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    22F, JC Plaza, 1225 West Nanjing Road Jing‘an District, Shanghai 200040
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.corxelbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
    China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill

    27 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/chinas-corxel-nabs-287m-series-d1-to-bankroll-glp-1-pill

    BIOSPACE
    27 Jan 2026
    Share Share
    Corxel secures $287M series D to fund oral GLP-1 studies
    Corxel secures $287M series D to fund oral GLP-1 studies

    23 Jan 2026

    // ENDPOINTS

    https://endpoints.news/china-founded-pharma-corxel-raises-up-to-287m-for-oral-glp-1/

    ENDPOINTS
    23 Jan 2026
    Share Share
    LENZ Therapeutics Submits NDA for LNZ100 to NMPA in China
    LENZ Therapeutics Submits NDA for LNZ100 to NMPA in China

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122426/0/en/LENZ-Therapeutics-Announces-NMPA-Submission-of-New-Drug-Application-for-LNZ100-in-China-for-the-Treatment-of-Presbyopia.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    ADA 2025: Phase 2 CX11/VCT220 Trial Data in China Revealed
    ADA 2025: Phase 2 CX11/VCT220 Trial Data in China Revealed

    23 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/23/3103347/0/en/Data-from-the-Phase-2-Clinical-Trial-of-CX11-VCT220-in-China-Presented-at-ADA-2025.html

    GLOBENEWSWIRE
    23 Jun 2025
    Share Share
    Corxel Gets FDA Approval for Phase 2 Trial of CX11 in Obesity
    Corxel Gets FDA Approval for Phase 2 Trial of CX11 in Obesity

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061377/0/en/CORXEL-Receives-Study-May-Proceed-Letter-from-the-U-S-FDA-for-the-Phase-2-Trial-of-CX11-in-Patients-with-Obesity-and-Overweight-Conditions.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search